1. Home
  2. NVG vs SUPN Comparison

NVG vs SUPN Comparison

Compare NVG & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen AMT-Free Municipal Credit Income Fund

NVG

Nuveen AMT-Free Municipal Credit Income Fund

HOLD

Current Price

$12.53

Market Cap

2.7B

Sector

Finance

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$51.66

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVG
SUPN
Founded
1999
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.6B
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
NVG
SUPN
Price
$12.53
$51.66
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$61.60
AVG Volume (30 Days)
568.8K
636.6K
Earning Date
01-01-0001
11-04-2025
Dividend Yield
4.65%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$681,539,000.00
Revenue This Year
N/A
$8.32
Revenue Next Year
N/A
$23.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
4.54
52 Week Low
$9.68
$29.16
52 Week High
$12.21
$57.65

Technical Indicators

Market Signals
Indicator
NVG
SUPN
Relative Strength Index (RSI) 45.37 67.82
Support Level $12.42 $51.01
Resistance Level $12.64 $52.30
Average True Range (ATR) 0.08 1.49
MACD -0.02 0.65
Stochastic Oscillator 29.28 89.77

Price Performance

Historical Comparison
NVG
SUPN

About NVG Nuveen AMT-Free Municipal Credit Income Fund

Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: